Axonics

Axonics, founded in 2012 and headquartered in Irvine, California, established itself as a disruptive force in the sacral neuromodulation (SNM) market with its full-body MRI-compatible, rechargeable implant systems for urinary urgency incontinence and fecal incontinence. Its technology challenged incumbent offerings with a 15+ year battery life and a streamlined implant procedure. Acquired by Boston Scientific in early 2024 for $3.7 billion, Axonics now functions as a key growth asset within Boston Scientific's urology portfolio, leveraging the larger company's global commercial infrastructure to expand access to its advanced neuromodulation therapies.

Miniaturized, rechargeable, full-body MRI-compatible implantable sacral neuromodulation (SNM) system for treating urinary and bowel dysfunction.

The primary competitor is Medtronic, the long-standing market leader in sacral neuromodulation. Axonics's technology directly challenged Medtronic's offerings on size, battery life, and MRI compatibility. Other competitors include Laborie (formerly Cogentix) and newer entrants. Post-acquisition, the competitive dynamic is now a battle between two medtech giants, Boston Scientific (via Axonics) and Medtronic, in the high-growth SNM segment.